Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AVNS vs ITGR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ITGR Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 7–3 Matrix Metrics)

ITGR Overall Winner 6-Pillar Tally: AVNS 3 – 3 ITGR Matrix Metrics: AVNS 3 – 7 ITGR

As of Nov 16, 2026, Integer Holdings Corporation (ITGR) is the stronger overall head-to-head candidate over Avanos Medical, Inc. (AVNS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). AVNS carries a Unified Composite Score of 56.7/100 (HOLD) at $24.99 (20.0x Forward P/E, 5.4% operating margin), whereas ITGR carries 65.8/100 (BUY) at $126.97 (18.4x Forward P/E, 9.8% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AVNS vs ITGR
AVNS NYSE
Avanos Medical, Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$24.99
+0.04% 1D
Market Cap $1.2B
TTM Revenue $716M
Forward P/E 20.0x
Beta / 30D Vol 1.22β · 6% Vol
Unified Composite Score
56.7 / 100 HOLD
Tech 75.0 Fund 59.0 Flow 50.0 Mom 46.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.0 · SMA20: $24.93 · SMA50: $24.90
ITGR NYSE Head-to-Head Winner
Integer Holdings Corporation
Electromedical & Electrotherapeutic Apparatus
$126.97
+0.21% 1D
Market Cap $4.3B
TTM Revenue $1.83B
Forward P/E 18.4x
Beta / 30D Vol 0.53β · 2% Vol
Unified Composite Score
65.8 / 100 BUY
Tech 59.0 Fund 61.0 Flow 60.0 Mom 58.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 63
RSI-14: 63.4 · SMA20: $126.62 · SMA50: $126.47

6-Pillar Scorecard Institutional Category Breakdown (AVNS 3 – 3 ITGR)

Columns: Metric · AVNS · ITGR
1. Valuation Multiples ITGR
Forward P/E 20.0x 18.4x
Trailing P/E 30.7x 42.5x
PEG Ratio N/M 2.81x
EV / Revenue 1.6x 3.1x
2. Growth & Scale AVNS
Revenue Growth (YoY) +8.8% -3.9%
Earnings Growth (YoY) -21.7% -61.3%
TTM Revenue (USD) $716M $1.83B
Market Cap $1.2B $4.3B
3. Profitability & Quality ITGR
Gross Margin 50.0% 25.1%
Operating Margin 5.4% 9.8%
Net Profit Margin -10.4% 5.7%
Return on Equity (ROE) -9.2% 6.0%
4. Balance Sheet & Cash Flow AVNS
Cash Generation (TTM) $56M EBITDA $83M
Cash Flow Margin 7.8% EBITDA Mgn 4.5%
Net Cash / Leverage $16.76 Book/Sh · -9.2% ROE $1.33B Net Debt (0.78x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ITGR
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 33.0% (50th %ile) 0.2% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat AVNS
OpEx & R&D Intensity 44.6% of Rev ($319M) 15.3% of Rev ($279M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AVNS (3) vs ITGR (7)
Institutional Metric AVNS ITGR Criterion Row Edge
Market Capitalization
Scale
$1.2B $4.3B Larger Scale ITGR
Trailing P/E Ratio
Valuation
30.7x 42.5x Lower Multiple AVNS
Forward P/E Ratio
Valuation
20.0x 18.4x Lower Multiple ITGR
Revenue Growth (YoY)
Growth
+8.8% -3.9% Higher Growth AVNS
Operating Margin (TTM)
Profitability
5.4% 9.8% Higher Margin ITGR
Net Profit Margin
Profitability
-10.4% 5.7% Higher Margin ITGR
Return on Equity (ROE)
Capital Efficiency
-9.2% 6.0% Higher ROE ITGR
52-Week Range Position
Momentum
97% ($9–$25) 91% ($67–$133) Stronger Trend AVNS
Beta / 30D Volatility
Risk Regime
1.22β · 6% Vol 0.53β · 2% Vol Lower Realized Risk ITGR
Unified Institutional Score
Composite Signal
56.7 / 100 (HOLD) 65.8 / 100 (BUY) Higher Composite ITGR
Trailing 12M Revenue (USD)
Operating Scale
$716M $1.83B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
50.0% 25.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.6x EV/Rev 2.81x PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$56M EBITDA ($16.76 Book/Sh · -9.2% ROE) $83M ($1.33B Net Debt (0.78x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ITGR +7.76 pp
AVNS: +0.16% · ITGR: +7.92%
3M Horizon ITGR +15.08 pp
AVNS: +1.13% · ITGR: +16.21%
6M Horizon AVNS +75.47 pp
AVNS: +90.76% · ITGR: +15.29%
1Y Horizon AVNS +67.76 pp
AVNS: +112.68% · ITGR: +44.92%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVNS vs ITGR. Trailing 12-month operating profitability (AVNS 5.4% vs ITGR 9.8%) and valuation multiples (AVNS 20.0x vs ITGR 18.4x Forward P/E) are benchmarked directly in Pillar 4 below.

AVNS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$716M
Gross Margin50.0%
Op. Margin5.4%
ROE / Fwd P/E-9.2% · 20.0x
ITGR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.83B
Gross Margin25.1%
Op. Margin9.8%
ROE / Fwd P/E6.0% · 18.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AVNS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 33.0%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVNS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ITGR CONSOLIDATION
71d in phase · OBV NEUTRAL
Current IV 0.2%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ITGR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AVNS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.2B market capitalization and 5.4% operating margin.
OpEx & R&D Reinvestment 44.6% of Rev ($319M)
90D Engineering Disclosures 0 Published
ITGR Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $4.3B market capitalization and 9.8% operating margin.
OpEx & R&D Reinvestment 15.3% of Rev ($279M)
90D Engineering Disclosures 0 Published

Investor FAQ AVNS vs ITGR Key Questions & Quantitative Answers

As of Nov 16, 2026, Integer Holdings Corporation (ITGR) is the stronger overall head-to-head candidate over Avanos Medical, Inc. (AVNS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). AVNS carries a Unified Composite Score of 56.7/100 (HOLD) at $24.99 (20.0x Forward P/E, 5.4% operating margin), whereas ITGR carries 65.8/100 (BUY) at $126.97 (18.4x Forward P/E, 9.8% operating margin). Technically, AVNS sits in a Neutral phase (RSI 57.0, UNCLASSIFIED options structure) and ITGR sits in a Neutral phase (RSI 63.4, CONSOLIDATION options structure).

AVNS leads the Growth & Scale pillar: AVNS posts +8.8% YoY revenue growth and -21.7% YoY earnings growth on $716M TTM revenue (50.0% gross margin, 5.4% operating margin), compared with ITGR at -3.9% YoY revenue growth and -61.3% YoY earnings growth on $1.83B TTM revenue (25.1% gross margin, 9.8% operating margin). On trailing 12-month operating scale, AVNS generates $716M in USD-normalized revenue versus $1.83B for ITGR. In operating R&D and SG&A reinvestment, AVNS deploys 44.6% of Rev ($319M) (0 90-day corporate R&D disclosures) versus 15.3% of Rev ($279M) (0 disclosures) for ITGR.

ITGR screens cheaper on headline valuation multiples. AVNS trades at 20.0x Forward P/E, 30.7x Trailing P/E, N/M PEG, and 1.6x EV/Revenue (7.8% EBITDA margin), whereas ITGR trades at 18.4x Forward P/E, 42.5x Trailing P/E, 2.81x PEG, and 3.1x EV/Revenue (4.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVNS (-9.2% ROE) versus ITGR (6.0% ROE) capital efficiency.

In options market volatility and institutional positioning, AVNS carries 33.0% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.22β · 6% Vol realized risk). By comparison, ITGR carries 0.2% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.53β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.